Ethical Issues in College Athletics by John Llewellyn, Steve May, 2013, Case Studies in Organizational Communications, May 2013 1. What clear examples of ethical lapses do you find in these case studies? 2. Does a president need a different perspective on the institution from that of an AD or coach? If so, why? How would one be established? Enforced? 3. What is the best action to be taken for the preservation of the institution's reputation in the cases recounted here? 4. How can ethical standards be maintained and defended in an environment where there is a strong sense that other competitors are bending/breaking the rules? 5. Do you know student who cheer for the team on game days but roll their eyes if a student- athlete struggles with issues in the classroom? What are the ethical dimensions of behavior as that? The Case of Wyeth, DesignWrite, and Premarin by Alexander Lyon and Mark Ricci, p.205, Case Studies in Organizational Communications, Steve May, 2013 1. To what extent is it ethical for Wyeth or other companies to use convert marketing tactics like ghostwritten medical journal articles? What marketing strategies would be ethical? 2. How ethical is it to publish research with handpicked favorable data? What ethical responsibilities do Wyeth and other pharmaceutical companies have to disclose unfavorable data about their drugs? 3. Are medical journal articles an appropriate channel though which to communicate marketing messages about medications? What are the likely long term consequences for physicians and patients? 4. What ethical obligations do medical ghostwriting firms like DesignWrite have to the physicians who read their work? To patients who take their medicine they promote? 5. Is it ethical for DesignWrite's employees not to list their names on their writings? In what ways does hiding the fact that Wyeth paid them for these articlesand listed expert physicians insteadmake the articles appear objective and unbiased? 6. What ethical responsibilities do physicians who signed on as authors have to journal editors, the scientific community, and Premarin patients generally? 7. To what extent is it ethical for physicians to frame themselves as authors of research in which they had no meaningful or genuine role? 8. What procedures or boundaries between doctors and pharmaceutical companies should be established to ensure more ethical working relationships and, by extension, patients' well-being and safety?